Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (®-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma by unknown
RESEARCH ARTICLE Open Access
Phase I/II dose-finding study of
nanoparticle albumin-bound paclitaxel
(nab®-Paclitaxel) plus Cisplatin as Treatment
for Metastatic Nasopharyngeal Carcinoma
Yan Huang1,2†, Wenhua Liang4,1,2†, Yunpeng Yang1,2†, Liping Zhao5,1,2, Hongyun Zhao1,2, Xuan Wu6,1,2,
Yuanyuan Zhao1,2, Yang Zhang1,2 and Li Zhang1,2,3,7*
Abstract
Background: This phase I/II study aimed to determine the maximum tolerated dose (MTD) of nanoparticle
albumin-bound paclitaxel (nab®-paclitaxel) plus cisplatin as treatment for metastatic nasopharyngeal
carcinoma (NPC).
Methods: Patients were enrolled into 1 of 3 dose cohorts, each with 21-day treatment cycles: 1)
intravenous (IV) nab-paclitaxel 260 mg/m2 on day 1; 2) IV nab-paclitaxel 140 mg/m2 on days 1 and 8; 3)
IV nab-paclitaxel 100 mg/m2 on days 1, 8, and 15. All patients received IV cisplatin 75 mg/m2 on day 1.
Treatment continued for 4–6 cycles, or until progression or unacceptable toxicity. If more than one-third of
the patients in a cohort experienced a dose-limiting toxicity (DLT), the dose used in the previous cohort
would be designated the MTD. Secreted protein acidic and rich in cysteine (SPARC) expression was
detected by immunohistochemistry staining.
Results: Sixty-nine patients were enrolled, of whom 64 and 67 were eligible for efficacy and safety analysis,
respectively. Two DLTs occurred in cohort 1 (grade 4 febrile neutropenia, grade 3 myalgia), none occurred
in cohort 2, and 2 occurred in cohort 3 (both grade 3 fatigue). The MTD was not reached. Partial responses
were achieved by 42 patients, 15 had stable disease, and 7 had progressive disease, giving an overall
response rate of 66 %. Median progression-free survival was 9 months (95 % CI, 6–12 months). Grade ≥ 3
adverse events were mainly hematologic. There was no significant difference between the 3 cohorts with
respect to efficacy or safety. Biomarker analyses indicated that stromal, rather than tumoral, SPARC may
predict the response to nab-paclitaxel in NPC.
Conclusions: Our findings suggest that nab-paclitaxel plus cisplatin is a highly active regimen with moderate
toxicity for the treatment of metastatic NPC, which warrants further investigation in a phase III study.
Trial registrations: ClinicalTrials.gov ID: NCT01735409. The trial was registered on November 20th, 2012.
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Background
Nasopharyngeal carcinoma (NPC) has a particularly high
incidence in Southern China (annual incidence > 20/
100,000 population [1–3]). Risk factors for NPC in-
clude, but are not limited to, Chinese ethnicity, male
gender, family history or a genetic predisposition,
smoking, and Epstein-Barr virus (EBV) infection [1, 2].
Platinum-based chemotherapy is the backbone of treat-
ment for metastatic or recurrent NPC [4–6], with
cisplatin or, less commonly, carboplatin typically being
administered with 1 or 2 other active chemotherapeutic
agents [4–6].
When combined with platinum-containing chemo-
therapy, paclitaxel has been shown to be effective in
the treatment of advanced or metastatic NPC [7–14].
Indeed, paclitaxel plus cisplatin or carboplatin com-
binations are now considered standard treatment op-
tions [4–6]. Traditional solvent-based paclitaxel is
highly hydrophobic, and is therefore formulated in a
mixture of polyoxyethylated castor oil (Cremophor
EL) and ethanol to facilitate intravenous (IV) infusion
[15]. Nanoparticle albumin-bound paclitaxel (nab®-
paclitaxel; ABRAXANE, Celgene, Summit, NJ, USA)
is a water-soluble form of paclitaxel linked to albumin
nanoparticles [16]. In a number of metastatic solid tu-
mors, nab-paclitaxel has shown similar or superior ef-
ficacy to traditional solvent-based paclitaxel, but with
an improved safety profile [17–20]. Indeed, its ap-
proval in combination with carboplatin for the treat-
ment of locally advanced metastatic non-small cell
lung cancer was based on clinical trial results de-
monstrating significantly improved response rates ver-
sus solvent-based paclitaxel plus carboplatin [19]. As
nab-paclitaxel is associated with a lower incidence of
neurological toxicities than solvent-based paclitaxel
[19], and in view of the potentially increased clinical
activity of cisplatin versus carboplatin [21, 22], we
decided to evaluate nab-paclitaxel in combination
with cisplatin in the treatment of metastatic NPC.
This phase I/II, dose-finding study (ClinicalTrials.gov
registration ID: NCT01735409) was designed to in-
vestigate the safety (especially with regard to neu-
rological effects), tolerability, and antitumor activity of
3 different doses/dosing schedules of nab-paclitaxel
when combined with cisplatin for the treatment of
metastatic NPC. As elevated expression of secreted
protein acidic and rich in cysteine (SPARC) is associ-
ated with metastasis and a poor prognosis in NPC
[23], evaluation of the relationship between SPARC
expression and the clinical activity of nab-paclitaxel
was an exploratory objective of the study. Investiga-
tion of the correlation between post-treatment EBV-




This was a single-center, single-arm, non-randomized,
open-label, phase I/II trial, conducted at the Sun Yat-sen
University Cancer Center in Guangzhou, China. Eligible
patients were enrolled into 3 dose cohorts, each with
21-day treatment cycles: cisplatin 75 mg/m2 IV on day 1
with sufficient hydration, plus nab-paclitaxel IV (30-min
infusion) at doses of: 260 mg/m2 on day 1 (cohort 1,
dose intensity 260 mg/m2 per cycle); 140 mg/m2 on days
1 and 8 (cohort 2, dose intensity 280 mg/m2 per cycle);
or 100 mg/m2 on days 1, 8, and 15 (cohort 3, dose inten-
sity 300 mg/m2 per cycle). Treatment was administered
for 4–6 cycles, or until disease progression or unaccept-
able toxicity.
It was planned that 23 patients would be enrolled into
each cohort. If more than one-third of patients in a
given cohort experienced a dose-limiting toxicity (DLT)
during all treatment cycles, enrollment would be
stopped and the dose used in the previous cohort would
be designated as the maximum tolerated dose (MTD).
At the initiation stage, we followed the routine mode
of dose escalation studies: we enrolled a total of 3 pa-
tients into cohort 1. After the 3 patients in this co-
hort completed the designated cycles of treatment,
and no more than 1 DLT occurred, we started cohort
2 and enrolled another 3 patients for dose checking
(the same for cohort 3). The cohorts that have com-
pleted the initiation stage then entered the expansion
stage and additional 20 participants were recruited.
Eligible patients were sequentially assigned to all ac-
tive cohorts (either in initiation stage or expansion
stage) one by one. If more than 1 patient experienced
DLT in the initiation stage or more than 1/3 of total
patients experienced DLT in the expanding stage of
any cohort, the corresponding cohort will be closed
and the remaining quota of the cohort would be re-
assigned to the previous dose cohort.
DLTs were defined as any of the following: National
Cancer Institute Common Terminology Criteria for
Adverse Events (NCI-CTCAE) grade 4 neutropenia last-
ing for > 7 days; neutropenia with fever (defined as an
absolute neutrophil count [ANC] < 1 × 109/L with a body
temperature of ≥ 38.3 °C); grade 4 thrombocytopenia, or
grade 3 thrombocytopenia with hemorrhage; grade ≥ 3
neuropathy; or any other grade ≥ 3 non-hematologic
toxicity that did not resolve following symptomatic treat-
ment. Concomitant medications without antineoplastic
activity were permitted, but their use was recorded.
The study was conducted according to the Declaration
of Helsinki, Good Clinical Practice guidelines, and local
regulatory requirements. The Ethics Committee of Sun
Yat-sen University approved the protocol. All patients
provided written informed consent.
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Treatment could be delayed for a maximum of
2 weeks to allow recovery from toxicity. For dose adjust-
ments, if patients suffered from grade 4 neutropenia or
thrombocytopenia, a 25 % reduction in nab-paclitaxel
was applied in the subsequent cycle/administration.
Subsequent dose escalation to the original dosage was
allowed providing the patient tolerated the doses given
at the 75 % level. For non-hematological toxicities,
nab-paclitaxel and cisplatin were reduced to a 75 %
dose if there were grade 3 toxicities, and the patient
went off-study with grade 4 toxicities, excluding those
due to nausea/vomiting or alopecia. Patients went off-
study if they suffered from grade 3 or worse neur-
opathy. Subsequent dose escalation was not allowed.
A maximum of 2 dose reductions per patient was
allowed.
Patients
Patients aged ≥ 18 years with a histologically proven diag-
nosis of NPC and evidence of metastatic disease were
enrolled. Principal inclusion criteria were: previous failure
or intolerance of standard treatment (prior chemotherapy
or radiotherapy up to one line) for advanced NPC, or
ineligibility for standard therapy (intermediate radiother-
apy for local disease); an Eastern Cooperative Oncology
Group performance status (ECOG PS) of 0–2; at least 1
measurable evaluable lesion; life expectancy of ≥ 12 weeks;
adequate hematologic (ANC > 1.5 × 109/L, platelet count >
100 × 109/L, and hemoglobin ≥ 90 g/L), hepatic (aspartate
aminotransferase [AST] and alanine aminotransferase
[ALT] < 2.5 × upper limit of normal [ULN], and bilirubin
< 1.0 × ULN), and renal (serum creatinine < 1.5 × ULN or
estimated creatinine clearance ≥ 60 mL/min [calculated
using the Cockcroft-Gault formula]; [24]) function; and
willingness to provide a biopsy sample for assessment of
SPARC expression.
Exclusion criteria included: treatment with either
more than 2 prior lines of anticancer therapy for
metastatic disease, or any chemotherapy, radiother-
apy, or other anticancer therapies within 3 weeks be-
fore enrollment; central nervous system metastases;
pre-existing peripheral neuropathy of NCI-CTCAE
grade ≥ 2; any active, clinically serious infection re-
quiring or likely to require antibiotics for > 4 weeks;
a life-threatening medical condition (e.g., congestive
heart failure, symptomatic coronary artery disease, or
heart block); a history of myocardial infarction within
3 months before enrollment; prior or current immuno-
deficiency; a history of allergy to paclitaxel or docetaxel;
or a previous or concurrent malignancy other than
NPC (except cervical carcinoma in situ, treated basal
cell carcinoma, superficial bladder tumors [Ta, Tis,




The primary endpoint was MTD (phase I setting). The
primary efficacy endpoint, (phase II setting) which was
used to estimate sample size, was the objective response
rate (ORR; defined as the proportion of patients with a
complete response [CR] or partial response [PR]) accord-
ing to Response Evaluation Criteria in Solid Tumors
(RECIST) version 1.1 [25]. Tumor assessment was under-
taken every 2 cycles, with best responses being recorded.
Responses were assessed by the investigator only.
Secondary endpoints
Secondary endpoints included: disease control rate (DCR;
defined as the proportion of patients with a CR, PR, or
best response of stable disease [SD]), and progression-free
survival (PFS) measured from the date of first infusion
until the date of progression or death.
Assessments
Safety assessments
Safety and tolerability were assessed by adverse event
(AE) monitoring and evaluation of vital signs, hepatic
and renal function, electrocardiograms, blood counts,
and changes in electrolytes. AEs were graded according
to NCI-CTCAE version 4.0.
Efficacy assessments
Antitumor activity was evaluated in the response-evaluable
population, defined as all patients whom completed 4–6 cy-
cles of treatment with post-baseline response assessments.
Safety endpoints were assessed in the safety population (all
patients who received ≥ 1 dose of study medication).
Assessment of EBV-DNA copy number
EBV-DNA copy number was evaluated at baseline and
after each chemotherapy cycle (before administration of
any study medication), using real-time, quantitative,
fluorescence-based polymerase chain reaction (PCR).




Assessment of SPARC expression
Immunohistochemical assessment of SPARC expression
was carried out at the end of enrollment. All the tissue
samples were stored samples that were obtained from
the primary lesion or metastatic lymph nodes before
curative radiotherapy or first-line chemotherapy. SPARC
were marked using mouse monoclonal antibody (Life
Technologies®, clone No., ON1-1). Expression was qu-
antified using H-score [26] for tumoral SPARC and Z-
score [27] for stromal SPARC.
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Statistical analyses
Sample size estimation
The clinical activity of nab-paclitaxel was assessed using
historical controls. The response rate of the most com-
monly used standard regimen of 5-fluorouracil and cis-
platin for the treatment of advanced NPC is 60 % [3].
Superiority of nab-paclitaxel plus cisplatin versus histor-
ical controls would be established if the ORR reached
70 %, based on a value of half the bilateral 95 % CI, 50–
90 %. To give a significance level (α) of 0.05 with 80 %
statistical power according to the Exact (Clopper-Pear-
son) approach, it was calculated that the study would
need to enroll 69 patients (23 in each cohort).
Statistical methods
For comparisons of baseline characteristics or rate of ef-
ficacy/toxicity among all cohorts, one-way ANOVA was
used to compare the means of continuous variables,
non-parametric test was used to compare the median
values, and R × C table Chi-square test was used to com-
pare the categorical parameters. For survival analyses,
time-to-event distribution was estimated using the
Kaplan-Meier method; the p value for the stratified log-
rank test was obtained from the score test. For all tests,
P value <0.05 was considered to be significant.
Subgroup analyses
Subgroup analyses were performed post-hoc, and in-
cluded: assessment of ORR in chemotherapy-naïve ver-
sus previously treated patients, and in paclitaxel-naïve
versus paclitaxel-pretreated patients; comparison of
DCR between patients with a > 10 % decrease in EBV-
DNA from baseline after cycle 1 versus those with a ≤
10 % decrease; and analysis of PFS in patients with ≤
30 %, > 30 to < 50 %, and ≥ 50 % tumor regression (de-
fined as the maximum decrease in the sum of the lon-
gest diameters of target lesions), and in patients with
complete EBV-DNA clearance at any time during treat-
ment versus those with non-zero trough EBV-DNA. Es-
timations and comparisons of PFS between the 3 dose
cohorts and the exploratory subgroups were carried out
by Kaplan-Meier methodology using a log-rank test.
Results
Patients
Between January 2013 and January 2014, 69 eligible
patients were enrolled: 23 into cohort 1, 22 into cohort
2, and 24 into cohort 3. In total, 64 patients received 4–
6 cycles of chemotherapy and were included in the
response-evaluable population. Five patients discontin-
ued the study before completing 4–6 cycles of chemo-
therapy for personal reasons (4 patients after 1 cycle,
owing to unwillingness to receive the study therapy, and
1 patient after 2 cycles for economic reasons). No
intolerable toxicities were reported in any of the 5 pa-
tients who withdrew prematurely. Sixty-seven patients
were included in the safety population (2 patients with-
drew after receiving only the first dose and were reluc-
tant to provide toxicity report. Thus, we were unable to
include them into the safety analysis.).
Demographics and baseline characteristics were balanced
between the 3 nab-paclitaxel dose cohorts (Table 1).
Dose-limiting toxicity and maximum tolerated dose
DLTs were observed in 2 patients in each of cohort 1
(grade 4 febrile neutropenia [cycle 2; managed using
granulocyte-colony stimulating factor] and grade 3 myal-
gia [cycle 1; managed using a COX-2 inhibitor]) and
cohort 3 (both grade 3 fatigue; cycles 1 and 2). All DLTs
resolved and the patients received a 25 % dose reduction
of nab-paclitaxel in all subsequent cycles. DLTs were not
reported in cohort 2. The incidence of DLTs did not
differ significantly between the 3 cohorts (cohort 1, 9 %;
cohort 2, 0 %; cohort 3, 8 %; P = 0.37). As less than one-
third of the patients in each cohort experienced a DLT,
the MTD was not reached.
Antitumor activity
Among the 64 evaluable patients, 42 achieved a PR, 15
had SD, and 7 had progressive disease, resulting in an
ORR of 66 % and a DCR of 89 % (Table 2). None of the
patients achieved a CR. Fig. 1 shows the maximum
change in the sum of the longest diameters of target
lesions for all 64 response-evaluable patients. One pa-
tient underwent a mixed response, partial response of
the pulmonary lesion but progressive disease of the
lesion at axillary lymph node, which was considered as
overall progressive disease in this study. No statistically
significant differences in ORR were observed between
the 3 dose cohorts (P = 0.94; Table 2).
In the post-hoc subgroup analyses, chemotherapy-
naïve patients achieved a significantly higher ORR than
chemotherapy-pretreated patients (100 % [17/17] vs.
53 % [25/47], respectively; P < 0.01). The ORR was
numerically, but not statistically significantly, higher
in paclitaxel-naïve than in paclitaxel-pretreated pa-
tients (58 % [18/31] vs. 44 % [7/16], respectively; P = 0.35).
When stratified according to EBV-DNA copy number,
patients with a > 10 % decrease in EBV-DNA from
baseline to cycle 1 achieved a DCR of 95 %, whereas,
patients with a ≤ 10 % decrease had a DCR of 76 %
(P = 0.02).
Median PFS among all evaluable patients was 9 months
(95 % CI, 6–12; Fig. 2a), and did not differ significantly
between the 3 dose cohorts (7 vs. 6 vs. 9 months, re-
spectively; P = 0.91; Fig. 2b). However, median PFS
did differ significantly between patients with a ≤ 30 %,
> 30 to < 50 %, and ≥ 50 % decrease in the sum of the
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longest diameters of target lesions (P = 0.001; Fig 2c).
Additionally, median PFS was significantly longer in
patients with complete EBV-DNA clearance at any
time during treatment than in those with non-zero
trough EBV-DNA (9 vs. 6 months, respectively; P = 0.02;
Fig. 2d).
Stromal SPARC overexpression predicted significantly
better response (74 % [40/54] vs. 29 % [2/7]; odds ratio
[OR] 7.1; 95 % CI, 1.2–41.1; P = 0.03) and prolonged PFS
(9 vs. 3 months; P = 0.01). However, SPARC expression on
the tumor cell surface alone failed to predict response to
treatment (74 % [29/39] vs. 59 % [13/22]; OR 1.4; 95 % CI,
Table 2 Tumor response according to RECIST version 1.1 (response-evaluable population)
Response Patients, n (%) Pa
All patients (N = 64) Cohort 1 (n = 22) Cohort 2 (n = 19) Cohort 3 (n = 23)
CR 0 0 0 0 NA
PR 42 (66) 15 (68) 12 (63) 15 (65) 0.94
SD 15 (23) 5 (23) 4 (21) 6 (26) 0.93
PD 7 (11) 2 (9) 3 (16) 2 (9) 0.72
ORR 42 (66) 15 (68) 12 (63) 15 (65) 0.94
DCR 57 (89) 20 (91) 16 (84) 21 (91) 0.72
Cohort 1, cisplatin 75 mg/m2 day 1 + nab-paclitaxel 260 mg/m2 day 1 Q3W; Cohort 2, cisplatin 75 mg/m2 day 1 + nab-paclitaxel 140 mg/m2 day 1, 8 Q3W; Cohort
3, cisplatin 75 mg/m2 day 1 + nab-paclitaxel 100 mg/m2 day 1, 8, 15 Q3W
aP value for the inter-cohort difference
NA, not applicable; PD, progressive disease
Table 1 Patient demographics and baseline characteristics (safety population)
Characteristic Cohort 1 (n = 23) Cohort 2 (n = 22) Cohort 3 (n = 24) Pa
Mean age, years (SD) 47 (10) 50 (10) 45 (12) 0.27
Male, n (%) 22 (96) 19 (86) 20 (83) 0.39
WHO histopathological grade, n (%) 0.77
Grade I 2 (9) 2 (9) 1 (4)
Grade II 0 0 0
Grade III 21 (91) 20 (91) 23 (96)
Current or past smoker, n (%) 13 (57) 15 (68) 14 (58) 0.69
Alcohol use, n (%) 19 (83) 18 (82) 19 (79) 0.95
Metastatic sites, n (%)
Lung 8 (35) 5 (22) 7 (29) 0.67
Liver 8 (35) 10 (45) 13 (54) 0.41
Bone 13 (57) 12 (55) 12 (50) 0.90
Distant lymph nodes 7 (30) 7 (32) 4 (17) 0.43
Multiple sites 10 (44) 10 (46) 10 (42) 0.97
Prior chemotherapy, n (%)
Any chemotherapy 16 (70) 15 (68) 20 (83) 0.43
Paclitaxel 5 (21) 4 (27) 9 (45) 0.49
Treatment history, n (%) 0.07
Failed 1st-line chemotherapy 15 (65) 10 (46) 12 (50)
Recurrence after curative treatment 1 (4) 6 (27) 9 (38)
Treatment-naïve 7 (30) 6 (27) 3 (13)
Median cycles of prior lines of chemotherapy (range) 5 (1 to 14) 5 (2 to 8) 4 (1 to 10) 0.75
Mean time since last chemotherapy, months (SD) 4 (4) 7 (11) 7 (8) 0.40
Prior radiotherapy, n (%) 10 (44) 11 (50) 17 (71) 0.143
Cohort 1, cisplatin 75 mg/m2 day 1 + nab-paclitaxel 260 mg/m2 day 1 Q3W; Cohort 2, cisplatin 75 mg/m2 day 1 + nab-paclitaxel 140 mg/m2 day 1, 8 Q3W; Cohort
3, cisplatin 75 mg/m2 day 1 + nab-paclitaxel 100 mg/m2 day 1, 8, 15 Q3W
aP value for the inter-cohort difference
Q3W, every 3 weeks; SD, standard deviation; WHO, World Health Organization
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0.7–2.8; P = 0.38). Representative examples of tumor sam-
ples stained for SPARC expression are shown in Fig. 3.
Safety
All patients included in the safety analysis experienced at
least 1 AE during treatment. AEs of grade ≥ 3 occurred in
51 patients (76 %). No patients discontinued the trial
because of AEs. There were a total of 285 events of dose
delaying and 21 events of dose reduction in a total of 628
administrations in 316 cycles (note: there are 1, 2 and 3
administrations per cycle in cohort 1, 2 and 3 respectively).
The most commonly reported AEs of any grade were
alopecia (97 %) and leucopenia (96 %; Table 3). Grade ≥ 3
AEs were mainly hematologic in nature. The most com-
mon were neutropenia (64 %) and leucopenia (54 %;
Table 3). Only one case experienced febrile neutropenia
but recovered soon after granulocyte colony stimulat-
ing factor treatment and empirically prophylactic anti-
biotic treatment, without any evidence of infection.
Non-hematologic grade ≥ 3 AEs that occurred in ≥ 5 % of
patients were vomiting (6 %), fatigue (5 %), and skin rash
(5 %). No grade 4 non-hematologic events occurred.
There were no significant differences between the 3
cohorts in the incidence of individual AEs (any grade or
grade ≥ 3), except for grade 1–2 edema, which was
significantly more common in cohort 3 (P = 0.004). One
patient from cohort 2 died during treatment (between
cycles 4 and 5) following a cerebral infarction; this was
thought to be partially related to treatment.
Discussion
Our results demonstrate moderate toxicity and substan-
tial antitumor activity of nab-paclitaxel plus cisplatin in
metastatic NPC, particularly among chemotherapy-naïve
patients.
Among evaluable patients, the ORR was 66 % (100 %
in chemotherapy-naïve patients), the DCR was 89 %, and
median PFS was 9 months. The high antitumor activity
of the nab-paclitaxel/cisplatin regimen reflects the
known chemosensitivity of NPC [3, 4]. The ORR of 66 %
is consistent with response rates reported for standard-
of-care, first- (50–90 %) and second-line (22–75 %)
platinum-based doublets in metastatic NPC [3]. The
100 % ORR in chemotherapy-naïve patients suggests
that nab-paclitaxel/cisplatin may be particularly active in
frontline use. However, as responses were seen in both
paclitaxel-naïve and paclitaxel-pretreated patients, prior
treatment with taxane-based therapy should not be
considered a barrier to treatment with nab-paclitaxel.
The median PFS of 9 months is also consistent with data
reported for active platinum-based doublets in meta-
static or recurrent NPC (median, 4–11 months; [3]). As
Fig. 1 Waterfall plot of maximum percentage change in the sum of the longest diameters of target lesions. PD was defined as an
increase of > 20 % in tumor size; PR was defined as a decrease of > 30 % in tumor size
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would be expected, patients in our study with the largest
reductions in tumor size had the longest PFS (Fig. 2c).
Toxicities associated with nab-paclitaxel and cisplatin
were predictable, generally acceptable, and manageable.
Only 4 DLTs were reported, and the MTD was not
reached. Toxicities associated with nab-paclitaxel and
cisplatin were mainly hematologic in nature, and were
typical of platinum/paclitaxel doublets in metastatic/re-
current NPC and other head and neck carcinomas [7–9,
28–33]. Grade ≥ 3 hematologic toxicities were observed
in the majority of patients; however, grade ≥ 3 non-
hematologic toxicities were relatively uncommon (inci-
dence ≤ 6 % for individual AEs), and there were no
reports of severe neuropathy. Although half the enrolled
population had received cisplatin-based first-line ther-
apy, we observed no intolerable aggravation of neur-
opathy among these patients. The overall incidence of
all-grade or grade 3/4 toxicities might be numerically
higher in this study than previous reports on nab-
paclitaxel regimens [17–20]. There are several potential
reasons; first, more than half of all included patients
were in 2nd line chemotherapy in this study, patients in
this group may be more susceptible to toxicity especially
hematological types. Second, all included patients were
Chinese. There is a relatively large body of evidence show-
ing that Asian populations experience higher incidence of
Fig. 2 Kaplan-Meier analysis of median progression free survival in: a, all study patients; b, all 3 nab-paclitaxel dose cohorts; c, patients
with ≤ 30 %, > 30 to < 50 %, and ≥ 50 % maximum decrease in the sum of the longest diameters of target lesions; and d, patients with
complete EBV-DNA clearance at any time during treatment versus those with non-zero trough EBV-DNA. Cohort 1, cisplatin 75 mg/m2 day
1 + nab-paclitaxel 260 mg/m2 day 1 Q3W; Cohort 2, cisplatin 75 mg/m2 day 1 + nab-paclitaxel 140 mg/m2 day 1, 8 Q3W; Cohort 3, cisplatin
75 mg/m2 day 1 + nab-paclitaxel 100 mg/m2 day 1, 8, 15 Q3W. CI, confidence interval
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or more severe toxicities at the standard dose com-
pared with Caucasians [34]. Third, since this is a
phase I/II study, we used a self-report form and more
intense inquiry strategy to track the toxicity event in
order not to miss any of the events we concerned,
which might contribute to higher recorded toxicity
than some historical data.
To our knowledge, this is the first dose-finding clinical
trial to evaluate nab-paclitaxel combined with cisplatin
alone in metastatic NPC. One important implication of
our results is that nab-paclitaxel combined with cisplatin
is a safe, tolerable regimen, especially with respect to
neuropathy. These findings can be projected to the treat-
ment of other malignant tumors, such as non-small cell
lung cancer and ovarian cancer.
Previous studies in other indications have shown that
nab-paclitaxel has an AE profile similar in nature to that
of conventional paclitaxel, but with a lower incidence of
some AEs (e.g., grade ≥ 3 neutropenia, arthralgia, and
myalgia), and without side effects usually attributed to
Cremophor EL, such as bronchospasms, hypotension,
and hypersensitivity reactions [17–19, 35]. Consistently,
no such AEs were observed in our study.
Neither toxicity (except for any-grade edema, which was
more common in the highest dose cohort) nor antitumor
activity differed significantly between the 3 nab-paclitaxel
dose cohorts. Based on these findings, and bearing in mind
the inconvenience of IV drug infusion, we recommend that
the nab-paclitaxel dose of 260 mg/m2 given on day 1 every
3 weeks should be taken forward into further studies of the
nab-paclitaxel/cisplatin combination in metastatic NPC.
EBV-DNA levels during treatment have been shown to
predict disease progression/relapse and overall survival
(OS) in both non-metastatic and metastatic NPC [36–42].
In our study, a reduction in EBV-DNA copy number during
treatment with nab-paclitaxel and cisplatin predicted both
disease control and prolonged PFS. Patients with a > 10 %
decrease in EBV-DNA from baseline after cycle 1 had a sta-
tistically higher DCR than patients with a ≤ 10 % decrease
(95 % vs. 76 %, respectively; P = 0.02). Similarly, patients
with complete EBV-DNA clearance during treatment had a
longer PFS than those with non-zero trough EBV-DNA
(median, 9 vs. 6 months, respectively; P = 0.02). Overall,
these results suggest that changes in EBV-DNA copy num-
ber may be a practical surveillance tool in patients with
metastatic NPC receiving nab-paclitaxel/cisplatin combin-
ation treatment.
SPARC overexpression has been associated with a re-
duced disease-free interval and poorer OS in patients
with head and neck cancer [43]. However, due to the
interaction between SPARC and albumin-bound drugs,
SPARC overexpression may be predictive of improved
outcomes following treatment with nab-paclitaxel in
head and neck cancer and advanced pancreatic cancer
Fig. 3 SPARC protein expression. Panels a (20× magnification) and c (40× magnification) show high stromal expression and low expression on
the tumor surface; panels b (20× magnification) and d (40× magnification) show that stromal expression is scarce, and there is little expression
on the tumor surface
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[44, 45], although this correlation was not found in
NSCLC cell lines [46]. In our study, stromal SPARC
overexpression strongly predicted a better response to
nab-paclitaxel (OR 7.1; 95 % CI, 1.2–41.1; P = 0.03) and
improved PFS (9 vs. 3 months; P = 0.01) than expression
at normal levels. By contrast, SPARC expression on the
surface of tumor cells was not predictive of a response.
This is similar to findings in an earlier phase I/II trial in
advanced pancreatic cancer, where only stromal SPARC
expression appeared to be an effective marker of
increased activity of nab-paclitaxel [45]. However, in the
phase III Metastatic Pancreatic Adenocarcinoma Clinical
Trial (MPACT) of nab-paclitaxel plus gemcitabine
versus gemcitabine alone, no association was found
between stromal, tumor epithelial, or plasma SPARC
expression and either survival or ORR in patients with
metastatic pancreatic cancer [47]. The contradictory
findings in these studies underline that further research
is needed to clarify whether, and in which cancer types,
SPARC expression may be a valuable tool to predict
response to nab-paclitaxel.
Conclusions
In conclusion, the results of the present phase I/II
trial suggest that, in patients with metastatic NPC,
nab-paclitaxel plus cisplatin is a highly active regimen
with moderate toxicity. Future studies may provide
further evidence to support a role for nab-paclitaxel
plus cisplatin in this indication. The raw data are
available in the (Additional file 1: Table S1).
Additional file
Additional file 1: Raw data that supports the conclusion. (XLS 763 kb)
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Table 3 Adverse events (NCI-CTCAE version 4.0) reported during treatment with nab-paclitaxel and cisplatin (safety population)

















Any type 67 (100) 23 (100) 21 (100) 23 (100) NA 51 (76) 17 (74) 17 (81) 17 (74) 0.82
Hematologicb
Leucopenia 64 (96) 21 (91) 21 (100) 22 (96) 0.38 36 (54) 10 (43) 13 (62) 13 (57) 0.45
Neutropenia 58 (87) 20 (87) 18 (86) 20 (87) 0.99 43 (64) 15 (65) 14 (67) 14 (61) 0.92
Anemia 55 (82) 16 (70) 19 (90) 20 (87) 0.15 6 (9) 3 (13) 1 (5) 2 (9) 0.63
Thrombocytopenia 18 (27) 8 (35) 5 (24) 5 (22) 0.57 0 0 0 0 NA
Non-hematologicc N = 64 n = 23 n = 18 n = 23 N = 64 n = 23 n = 18 n = 23
Alopecia 62 (97) 21 (91) 21 (91) 23 (100) 0.16 0 0 0 0 NA
Fatigue 57 (89) 21 (91) 17 (94) 19 (83) 0.44 3 (5) 1 (4) 0 2 (9) 0.42
Anorexia 53 (83) 21 (91) 16 (89) 16 (70) 0.11 0 0 0 0 NA
Myasthenia 52 (81) 18 (78) 17 (94) 17 (74) 0.22 2 (3) 0 0 2 (9) 0.16
Neuropathy 46 (72) 17 (74) 15 (83) 14 (61) 0.27 0 0 0 0 NA
Constipation 42 (66) 14 (61) 15 (83) 13 (57) 0.17 0 0 0 0 NA
Nausea 40 (63) 15 (65) 13 (72) 12 (52) 0.40 0 0 0 0 NA
Arthralgia 39 (61) 16 (70) 12 (67) 11 (48) 0.27 1 (2) 1 (4) 0 0 0.40
Vomiting 38 (59) 11 (48) 14 (78) 13 (57) 0.14 4 (6) 1 (4) 3 (17) 0 0.08
Skin rash 35 (55) 14 (61) 8 (44) 13 (57) 0.56 3 (5) 2 (9) 1 (6) 0 0.37
Myalgia 34 (53) 10 (43) 10 (56) 14 (61) 0.48 1 (2) 1 (4) 0 0 0.40
Pruritus 32 (50) 15 (65) 5 (28) 12 (52) 0.06 0 0 0 0 NA
Diarrhea 21 (33) 8 (35) 6 (33) 7 (30) 0.95 1 (2) 0 1 (6) 0 0.27
Edema 20 (31) 5 (22) 2 (11) 13 (57) 0.004 0 0 0 0 NA
Cohort 1, cisplatin 75 mg/m2 day 1 + nab-paclitaxel 260 mg/m2 day 1 Q3W; Cohort 2, cisplatin 75 mg/m2 day 1 + nab-paclitaxel 140 mg/m2 day 1, 8 Q3W; Cohort
3, cisplatin 75 mg/m2 day 1 + nab-paclitaxel 100 mg/m2 day 1, 8, 15 Q3W
aP value for the inter-cohort difference
bBlood samples for hematologic AE assessment were available for 67 patients
cNon-hematologic AEs were assessed in the 64 patients who completed 4–6 cycles
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Response Evaluation Criteria in Solid Tumors; SPARC, Secreted protein acidic
and rich in cysteine; SD, stable disease; ULN, upper limit of normal.
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